Multiple Myeloma 2020

Researchers used next-generation sequencing to analyze the landscape of neoantigens, identifying neoantigen-specific immune cells triggered by immunotherapy.

In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them.

The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.

A study analyzed a test for specific gene patterns that could indicate that a patient will not respond to standard treatment for newly diagnosed multiple myeloma.

Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai highlighted multiple myeloma treatments that he believes have shown promise over the past year.

The clinical researcher discussed areas of multiple myeloma which she believes deserve further assessment.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.

Clinical researcher Lisa La discussed advancements in multiple myeloma research and where she hopes the field continues to expand.

The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.